We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

First-Of-Its-Kind Microchannel Drug Delivery Technology to Enable Self-Administrable COVID-19 Vaccines

By HospiMedica International staff writers
Posted on 20 Aug 2020
Print article
Illustration
Illustration
A first-of-its-kind microchannel drug delivery technology could enable self-administrable COVID-19 vaccines, enhancing their potential.

The drug delivery technology has been developed by Aquavit Pharmaceuticals, Inc. (New York, NY, USA) which is working on several innovative products and platform technology IP for personalized medicine. Aquavit has filed its latest patent for its novel drug delivery device through the COVID-19 Prioritized Examination Pilot Program (PEPP) which has been rolled out by the United States Patent and Trademark Office (USPTO) in light of the COVID-19 outbreak to facilitate moving patents for medical devices and services designed to combat the virus to market as soon as possible.

Currently, the majority of existing commercial vaccines are delivered to intramuscular or subcutaneous tissues by needle and syringe. However, in the past few years, there has been a renewed interest in the exploitation of skin vaccination in pursuit of a more potent immune response considering that the skin but not the muscle contains large amounts of antigen-presenting cells (APCs). The major challenge posed by targeting vaccines to the epidermis is to accurately and efficiently access the target tissue. Although the epidermis is superficially located and has a large surface area, access is restricted by the overlying stratum corneum, which forms a physical barrier to molecules > 500 Da molecular weight. Additionally, the epidermal layer is too thin to be reliably accessed by traditional needle and syringe injection.

Aquavit is developing a single-use epidermal drug delivery device that aids in the method of self-administration of biologics, drugs, vaccines, etc. using a microchannel delivery apparatus. The needle features a patented screw thread design that allows the delivery of biologics and vaccines to the epidermis/papillary dermis. Unlike syringe needles and microneedles, the microchannel systems are painless, user-friendly and require a low learning curve.
Aquavit's COVID-19 vaccine device patent covers new devices, compositions and methods that enable the administration of therapeutic vaccine compositions using microchannel delivery into these hard to reach epidermal and dermal layers of the skin rich in Antigen Presenting Cells (APCs) for promoting effective immune responses. The methods and devices are particularly useful during times of epidemic and pandemic crises, such as the current COVID-19 pandemic, when there is no or limited access to health care providers and healthcare systems are strained or limited. Being able to self-administer or have the administration performed by a non-health care provider also reduces the risk that the patient may become infected by visiting a hospital or health care provider where there are many infected patients.

"Multiple studies have proven that intradermal delivery is more effective and cost-efficient than intramuscular delivery. We believe our technology can potentially achieve higher immunogenicity than traditional needle methods, while also having higher patient compliance and accessibility," said Sai Sankar, Aquavit's Chief Biomedical Engineer.

"With the USPTO's fast track program, Aquavit is one step closer to manufacture and commercialize this novel drug delivery device that enhances the potential of any COVID-19 vaccine," said Sobin Chang, MPH, Chief Executive Officer. "As many pharmaceutical companies rush to develop a COVID-19 vaccine, there is an urgent need for integral components and delivery technology. Our universal platform technology can potentially accommodate any vaccines to be self-administered and pandemic distribution ready. We are currently in talks with multiple global scale pharmaceutical companies, vaccine makers, and major universities for collaborations and partnerships."

Related Links:

Aquavit Pharmaceuticals, Inc.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Doppler String Phantom
CIRS Model 043A
New
Documentation System For Blood Banks
HettInfo II

Print article
Radcal

Channels

Critical Care

view channel
mage: The electroceutical epidermal patch is designed to inhibit bacterial growth (Photo courtesy of Saehyun Kim/University of Chicago)

Cutting-Edge Bioelectronic Device Offers Drug-Free Approach to Managing Bacterial Infections

Antibiotic-resistant infections pose an increasing threat to patient safety and healthcare systems worldwide. Recent estimates indicate that drug-resistant infections may rise by 70% by 2050, highlighting... Read more

Surgical Techniques

view channel
Image: Conceptual schematic showing microgrippers (µ-grippers) operating as biopsy tools in the upper urinary tract (Photo courtesy of Wangqu Liu, Yan Wan/Gracias Lab, Johns Hopkins University)

Microgrippers For Miniature Biopsies to Create New Cancer Diagnostic Screening Paradigm

The standard diagnosis of upper urinary tract cancers typically involves the removal of suspicious tissue using forceps, a procedure that is technically challenging and samples only a single region of the organ.... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more